Quest Diagnostics Incorporated
DGXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. The $26.17B market capitalization puts DGX squarely in large-cap range for its industry. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Market Cap
$26.17B
Beta
0.55
P/E (TTM)
25.20
P/E (Fwd)
19.67
EPS (TTM)
$9.41
EPS (Fwd)
$12.06
ROE
14.6%
ROA
6.4%
Cash
$626.0M
Total Debt
$6.40B
Free CF
$909.6M
52W Change
29.8%
Annual Financials
Cash vs Debt
Where DGX stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, DGX finished 20.13% above its 150-day moving average ($203.54) and 23.75% above its 200-day moving average ($197.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DGX overbought or oversold?
At the August 26, 2026 close, DGX's RSI(14) was 72.4, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Quest Diagnostics Incorporated carries $6.40B in total debt against $626.0M in cash reserves — debt is roughly 10.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $909.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 14.6%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $9.88B to $11.04B.
The relatively low beta of 0.55 suggests DGX is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Quest Diagnostics Incorporated's trajectory.